Ajay Madan - 28 Oct 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Development Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 28 Oct 2021
Net transactions value: +$77,660
Form type: 4
Filing time: 01 Nov 2021, 19:11:16 UTC
Next filing: 04 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$77,660	+106,383	+136%	$0.7300^*	184,671	28 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Options Exercise	$0	-106,383	-100%	$0.000000^*	0	28 Oct 2021	Common Stock	106,383	$0.7300	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 772 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
F2	25% of the shares subject to the option vested on July 17, 2017 and 1/48th of the total remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.